4D Molecular Therapeutics (FDMT) signs $85M upfront license deal with Otsuka for 4D-150 in APAC

4D Molecular Therapeutics, Inc.

Upfront cash payment of $85M from Otsuka; additional cost sharing of at least $50M over next three years.
Potential regulatory and commercial milestones up to $335.5M, plus tiered double-digit royalties on net sales in APAC.
Otsuka gains exclusive rights to develop and commercialize 4D-150 for wet AMD and DME in Japan, China, Australia, and other APAC markets.
Phase 3 study 4FRONT-1 enrollment exceeds expectations: over 200 patients randomized as of Oct 30, 2025.
FDMT retains full rights outside APAC, including US, Latin America, and Europe.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.